Altimmune Inc (ALT) - Total Liabilities
Based on the latest financial reports, Altimmune Inc (ALT) has total liabilities worth $55.04 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check ALT asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Altimmune Inc - Total Liabilities Trend (2005–2025)
This chart illustrates how Altimmune Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Altimmune Inc assets under control.
Altimmune Inc Competitors by Total Liabilities
The table below lists competitors of Altimmune Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
NOVA Technology Corporation Limited
SHE:300921
|
China | CN¥140.10 Million |
|
Moura Dubeux Engenharia S.A
SA:MDNE3
|
Brazil | R$3.67 Billion |
|
Kumyang
KO:001570
|
Korea | ₩750.35 Billion |
|
Dongwon System
KO:014820
|
Korea | ₩701.13 Billion |
|
Objective Corporation Ltd
AU:OCL
|
Australia | AU$86.59 Million |
|
Bel Fuse A Inc
NASDAQ:BELFA
|
USA | $416.53 Million |
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
Turkey | TL10.00 Billion |
|
Stor-Age Property REIT Ltd
JSE:SSS
|
South Africa | ZAC5.34 Billion |
Liability Composition Analysis (2005–2025)
This chart breaks down Altimmune Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Altimmune Inc (ALT) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 18.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Altimmune Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Altimmune Inc (2005–2025)
The table below shows the annual total liabilities of Altimmune Inc from 2005 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $55.04 Million | +248.38% |
| 2024-12-31 | $15.80 Million | -4.49% |
| 2023-12-31 | $16.54 Million | -23.55% |
| 2022-12-31 | $21.64 Million | +9.65% |
| 2021-12-31 | $19.73 Million | +2.55% |
| 2020-12-31 | $19.24 Million | +125.34% |
| 2019-12-31 | $8.54 Million | +32.62% |
| 2018-12-31 | $6.44 Million | -55.14% |
| 2017-12-31 | $14.35 Million | -93.01% |
| 2016-12-31 | $205.28 Million | +6288.49% |
| 2015-12-31 | $3.21 Million | -13.25% |
| 2014-12-31 | $3.70 Million | -62.22% |
| 2013-12-31 | $9.80 Million | -11.42% |
| 2012-12-31 | $11.07 Million | +59.21% |
| 2011-12-31 | $6.95 Million | -53.62% |
| 2010-12-31 | $14.99 Million | -53.42% |
| 2009-12-31 | $32.18 Million | -14.02% |
| 2008-12-31 | $37.43 Million | +43.74% |
| 2007-12-31 | $26.04 Million | +78.04% |
| 2006-12-31 | $14.63 Million | +3462.43% |
| 2005-12-31 | $410.54K | -- |
About Altimmune Inc
Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity, metabolic, and liver diseases. Its lead product candidate is pemvidutide, a GLP-1/glucagon dual receptor agonist, which is in Phase 3 trial for the treatment of obesity and metabolic associated steatohepatitis. The company was founded in 1997 and is headquartered in Gaithersburg, Maryland.